Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia

[1]  Dae-Ho Lee,et al.  Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non‐Hodgkin's lymphoma , 2009, Transfusion.

[2]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[3]  L. Rybicki,et al.  Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies , 2007, Bone Marrow Transplantation.

[4]  G. Marcucci,et al.  Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  Jeffrey S. Miller,et al.  Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  L. Rybicki,et al.  Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Lemeshow,et al.  Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation , 2004, Bone Marrow Transplantation.

[8]  J. Vose,et al.  Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. , 2003, Blood.

[9]  J. Wingard,et al.  Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation , 2003, Leukemia & lymphoma.

[10]  M. Munsell,et al.  Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  T. Lister,et al.  Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Nademanee,et al.  Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. , 2000, Blood.

[13]  J. Armitage,et al.  International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Armitage,et al.  International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Copelan,et al.  Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Chan,et al.  Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Neuberg,et al.  Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.